AstraZeneca PLC AZNCF Stock
AstraZeneca PLC Price Chart
AstraZeneca PLC AZNCF Financial and Trading Overview
| AstraZeneca PLC stock price | 187.45 USD |
| Previous Close | 184.32 USD |
| Open | 178.29 USD |
| Bid | 176.31 USD x 10100 |
| Ask | 192.79 USD x 10000 |
| Day's Range | 178.29 - 178.29 USD |
| 52 Week Range | 122.26 - 195 USD |
| Volume | 200 USD |
| Avg. Volume | 161.84K USD |
| Market Cap | 290.6B USD |
| Beta (5Y Monthly) | 0.192 |
| PE Ratio (TTM) | 31.086233 |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | 3.21 (1.70%) |
| Ex-Dividend Date | August 7, 2025 |
| 1y Target Est | 104 USD |
AZNCF Valuation Measures
| Enterprise Value | 316.79B USD |
| Trailing P/E | 31.086233 |
| Forward P/E | 37.045456 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 4.999409 |
| Price/Book (mrq) | 6.335767 |
| Enterprise Value/Revenue | 5.45 |
| Enterprise Value/EBITDA | 15.517 |
Trading Information
AstraZeneca PLC Stock Price History
| Beta (5Y Monthly) | 0.192 |
| 52-Week Change | 23.72% |
| S&P500 52-Week Change | 32.69% |
| 52 Week High | 195 USD |
| 52 Week Low | 122.26 USD |
| 50-Day Moving Average | 183.86 USD |
| 200-Day Moving Average | 161.39 USD |
AZNCF Share Statistics
| Avg. Volume (3 month) | 161.84K USD |
| Avg. Daily Volume (10-Days) | 978.97K USD |
| Shares Outstanding | 1.55B |
| Float | 1.54B |
| Short Ratio | N/A |
| % Held by Insiders | 0.027% |
| % Held by Institutions | 56.02% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 3.13 |
| Trailing Annual Dividend Yield | 1.69% |
| 5 Year Average Dividend Yield | 217.00% |
| Payout Ratio | 0.5205 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | September 30, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | 16.17% |
| Operating Margin (ttm) | 24.10% |
| Gross Margin | 83.25% |
| EBITDA Margin | 35.12% |
Management Effectiveness
| Return on Assets (ttm) | 9.06% |
| Return on Equity (ttm) | 21.67% |
Income Statement
| Revenue (ttm) | 58.13B USD |
| Revenue Per Share (ttm) | 37.5 USD |
| Quarterly Revenue Growth (yoy) | 12.00% |
| Gross Profit (ttm) | 48.4B USD |
| EBITDA | 20.42B USD |
| Net Income Avi to Common (ttm) | 9.4B USD |
| Diluted EPS (ttm) | 6.03 |
| Quarterly Earnings Growth (yoy) | 77.29% |
Balance Sheet
| Total Cash (mrq) | 8.18B USD |
| Total Cash Per Share (mrq) | 5.28 USD |
| Total Debt (mrq) | 32.66B USD |
| Total Debt/Equity (mrq) | 71.05 USD |
| Current Ratio (mrq) | 0.879 |
| Book Value Per Share (mrq) | 29.586 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 15.14B USD |
| Levered Free Cash Flow (ttm) | 9.98B USD |
Profile of AstraZeneca PLC
| Country | United States |
| State | N/A |
| City | Cambridge |
| Address | 1 Francis Crick Avenue |
| ZIP | CB2 0AA |
| Phone | 44 20 3749 5000 |
| Website | https://www.astrazeneca.com |
| Industry | Drug Manufacturers - General |
| Sector(s) | Healthcare |
| Full Time Employees | 94300 |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple next-generation therapies for obesity and type 2 diabetes; and collaboration Revna Biosciences for lung cancer treatment. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Q&A For AstraZeneca PLC Stock
What is a current AZNCF stock price?
AstraZeneca PLC AZNCF stock price today per share is 187.45 USD.
How to purchase AstraZeneca PLC stock?
You can buy AZNCF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for AstraZeneca PLC?
The stock symbol or ticker of AstraZeneca PLC is AZNCF.
Which industry does the AstraZeneca PLC company belong to?
The AstraZeneca PLC industry is Drug Manufacturers - General.
How many shares does AstraZeneca PLC have in circulation?
The max supply of AstraZeneca PLC shares is 1.55B.
What is AstraZeneca PLC Price to Earnings Ratio (PE Ratio)?
AstraZeneca PLC PE Ratio is 0.00000000 now.
What was AstraZeneca PLC earnings per share over the trailing 12 months (TTM)?
AstraZeneca PLC EPS is 0 USD over the trailing 12 months.
Which sector does the AstraZeneca PLC company belong to?
The AstraZeneca PLC sector is Healthcare.


